Page 1676 - Williams Hematology ( PDFDrive )

1650 Part XI: Malignant Lymphoid Diseases Chapter 99: Follicular Lymphoma 1651

indolent lymphoma: Results of the randomized phase III ECOG1496 Study. J Clin 68. Brody J, Kohrt H, Marabelle A, et al: Active and passive immunotherapy for lymphoma:
Oncol 27:1607–1614, 2009. Proving principles and improving results. J Clin Oncol 29:1864–1875, 2011.
45. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with 69. Schuster SJ, Neelapu SS, Gause BL, et al: Vaccination with patient-specific tumor-
cyclophosphamide, vincristine, and prednisone alone in patients with previously derived antigen in first remission improves disease-free survival in follicular
untreated advanced follicular lymphoma. J Clin Oncol 26:4579–4586, 2008. lymphoma. J Clin Oncol 29:2787–2794, 2011.
46. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added 70. Rohatiner AZ, Nadler L, Davies AJ, et al: Myeloablative therapy with autologous bone
to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone marrow transplantation for follicular lymphoma at the time of second or subsequent
(CHOP) significantly improves the outcome for patients with advanced-stage follicular remission: Long-term follow-up. J Clin Oncol 25:2554–2559, 2007.
lymphoma compared with therapy with CHOP alone: Results of a prospective random- 71. Schouten HC, Qian W, Kvaloy S, et al: High-dose therapy improves progression-free
ized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725–3732, survival and survival in relapsed follicular non-Hodgkin’s lymphoma: Results from the
2005. randomized European CUP trial. J Clin Oncol 21:3918–3927, 2003.
47. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chloram- 72. Deconinck E, Foussard C, Milpied N, et al: High-dose therapy followed by autologous
bucil, and prednisolone chemotherapy followed by interferon maintenance prolongs purged stem-cell transplantation and doxorubicin-based chemotherapy in patients
survival in patients with advanced follicular lymphoma: An East German Study Group with advanced follicular lymphoma: A randomized multicenter study by GOELAMS.
Hematology and Oncology Study. J Clin Oncol 25:1986–1992, 2007. Blood 105:3817–3823, 2005.
48. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with 73. Lenz G, Dreyling M, Schiegnitz E, et al: Myeloablative radiochemotherapy followed by
CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417–1423, autologous stem cell transplantation in first remission prolongs progression-free sur-
2005. vival in follicular lymphoma: Results of a prospective, randomized trial of the German
49. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combina- Low-Grade Lymphoma Study Group. Blood 104:2667–2674, 2004.
tion of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases 74. Bierman PJ, Sweetenham JW, Loberiza FR, Jr., et al: Syngeneic hematopoietic stem-
the response rate and prolongs survival as compared with FCM alone in patients with cell transplantation for non-Hodgkin’s lymphoma: A comparison with allogeneic and
relapsed and refractory follicular and mantle cell lymphomas: Results of a prospec- autologous transplantation—The Lymphoma Working Committee of the International
tive randomized study of the German Low-Grade Lymphoma Study Group. Blood Bone Marrow Transplant Registry and the European Group for Blood and Marrow
104:3064–3071, 2004. Transplantation. J Clin Oncol 21:3744–3753, 2003.
50. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and 75. van Besien K, Loberiza FR, Jr., Bajorunaite R, et al: Comparison of autologous and
interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood
study. Blood 112:4824–4831, 2008. 102:3521–3529, 2003.
51. Press OW, Palanca-Wessels MC: Selection of first-line therapy for advanced follicular 76. Rezvani AR, Storer B, Maris M, et al: Nonmyeloablative allogeneic hematopoietic
lymphoma. J Clin Oncol 31:1496–1498, 2013. cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s
52. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab versus lymphoma. J Clin Oncol 26:211–217, 2008.
CHOP plus rituximab as first-line treatment for patients with indolent and mantle- 77. Khouri IF, Saliba RM, Erwin WD, et al: Nonmyeloablative allogeneic transplantation
cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed
Lancet 381:1203–1210, 2013. follicular lymphoma: 12-year results. Blood 119:6373–6378, 2012.
53. Flinn IW, Van der Jagt RH, Kahl BS, et al: An open-label, randomized study of benda- 78. Al-Tourah AJ, Gill KK, Chhanabhai M, et al: Population-based analysis of incidence
mustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol 26:5165–5169,
and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, 2008.
and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent 79. Montoto S, Davies AJ, Matthews J, et al: Risk and clinical implications of transformation
non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright Study. of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426–2433,
Blood 123(19):2944–2952, 2014. 2007.
54. van Oers MH, Van Glabbeke M, Giurgea L, et al: Rituximab maintenance treatment 80. Oviatt DL, Cousar JB, Collins RD, et al: Malignant lymphomas of follicular center cell
of relapsed/resistant follicular non-Hodgkin’s lymphoma: Long-term outcome of the origin in humans. V. Incidence, clinical features, and prognostic implications of trans-
EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28:2853–2858, 2010. formation of small cleaved cell nodular lymphoma. Cancer 53:1109–1114, 1984.
55. Goldenberg DM, Sharkey RM: Advances in cancer therapy with radiolabeled monoclo- 81. Link BK, Maurer MJ, Nowakowski GS, et al: Rates and outcomes of follicular lym-
nal antibodies. Q J Nucl Med Mol Imaging 50:248–264, 2006. phoma transformation in the immunochemotherapy era: A report from the University
56. Press OW: Evidence mounts for the efficacy of radioimmunotherapy for B-cell lympho- of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemi-
mas. J Clin Oncol 26:5147–5150, 2008. ology Resource. J Clin Oncol 31:3272–3278, 2013.
57. Kaminski MS, Estes J, Zasadny KR, et al: Radioimmunotherapy with iodine (131) 82. Villa D, Crump M, Panzarella T, et al: Autologous and allogeneic stem-cell transplanta-
I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated tion for transformed follicular lymphoma: A report of the Canadian blood and marrow
results and long-term follow-up of the University of Michigan experience. Blood 96: transplant group. J Clin Oncol 31:1164–1171, 2013.
1259–1266, 2000. 83. Advani RH, Buggy JJ, Sharman JP, et al: Bruton tyrosine kinase inhibitor ibrutinib
58. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malig-
radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s nancies. J Clin Oncol 31:88–94, 2013.
lymphoma. J Clin Oncol 20:3262–3269, 2002. 84. Wang ML, Rule S, Martin P, et al: Targeting BTK with ibrutinib in relapsed or refractory
59. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90- mantle-cell lymphoma. N Engl J Med 369:507–516, 2013.
labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunother- 85. Flinn IW, Kahl BS, Leonard JP, et al: Idelalisib, a selective inhibitor of phosphatidylinos-
apy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell itol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma.
non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463, 2002. Blood 123:3406–3413, 2014.
60. Witzig TE: The use of ibritumomab tiuxetan radioimmunotherapy for patients with 86. Gopal AK, Kahl BS, de Vos S, et al: PI3Kdelta inhibition by idelalisib in patients with
relapsed B-cell non-Hodgkin’s lymphoma. Semin Oncol 27:74–78, 2000. relapsed indolent lymphoma. N Engl J Med 370:1008–1018, 2014.
61. Davis TA, Kaminski MS, Leonard JP, et al: The radioisotope contributes significantly to 87. Davids MS, Letai A: ABT-199: Taking dead aim at BCL-2. Cancer Cell 23:139–141,
the activity of radioimmunotherapy. Clin Cancer Res 10:7792–7798, 2004. 2013.
62. Kaminski MS, Tuck M, Estes J, et al: 131I-tositumomab therapy as initial treatment for 88. Souers AJ, Leverson JD, Boghaert ER, et al: ABT-199, a potent and selective BCL-2
follicular lymphoma. N Engl J Med 352:441–449, 2005. inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202–208,
63. Leonard JP, Coleman M, Kostakoglu L, et al: Abbreviated chemotherapy with fludara- 2013.
bine followed by tositumomab and iodine I 131 tositumomab for untreated follicular 89. Palanca-Wessels MC, Press OW: Advances in the treatment of hematologic malignan-
lymphoma. J Clin Oncol 23:5696–5704, 2005. cies using immunoconjugates. Blood 123:2293–2301, 2014.
64. Press OW, Unger JM, Braziel RM, et al: Phase II trial of CHOP chemotherapy followed 90. Kochenderfer JN, Rosenberg SA: Treating B-cell cancer with T cells expressing
by tositumomab/iodine I-131 tositumomab for previously untreated follicular non- anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 10:267–276, 2013.
Hodgkin’s lymphoma: Five-year follow-up of Southwest Oncology Group Protocol 91. Budde LE, Berger C, Lin Y, et al: Combining a CD20 chimeric antigen receptor and an
S9911. J Clin Oncol 24:4143–4149, 2006. inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive
65. Morschhauser F, Radford J, Van Hoof A, et al: 90Yttrium-ibritumomab tiuxetan con- immunotherapy for lymphoma. PLoS One 8:e82742, 2013.
solidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: 92. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival
Updated results after a median follow-up of 7.3 years from the international, random- of patients with follicular lymphoma. J Clin Oncol 23:8447–8452, 2005.
ized, phase III first-line indolent trial. J Clin Oncol 31:1977–1983, 2013. 93. Liu Q, Fayad L, Cabanillas F, et al: Improvement of overall and failure-free survival in
66. Rohatiner AZ, Gregory WM, Peterson B, et al: Meta-analysis to evaluate the role of stage IV follicular lymphoma: 25 years of treatment experience at The University of
interferon in follicular lymphoma. J Clin Oncol 23:2215–2223, 2005. Texas M.D. Anderson Cancer Center. J Clin Oncol 24:1582–1589, 2006.
67. Freedman A, Neelapu SS, Nichols C, et al: Placebo-controlled phase III trial of 94. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lym-
patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage phoma patients in the United States. J Clin Oncol 23:5019–5026, 2005.
colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin
Oncol 27:3036–3043, 2009.

Kaushansky_chapter 99_p1641-1652.indd 1651 9/18/15 3:57 PM